Senex Biotechnology is a drug discovery and development company focused on cancer therapeutics. Senex’s lead program targets a protein that regulates gene expression and is required by cancer cells to adapt to adversarial conditions; such adaptation leads to cancer drug resistance and metastasis. Senex is developing highly selective small-molecule inhibitors of this protein for the treatment of presently incurable types of prostate cancer, breast cancer and leukemia. We are also investigating the utility of these inhibitors for different cancers in combination with other therapeutics, as well as for inflammation, cardiovascular and other diseases. Our latest, highly potent and selective drug candidate is anticipated to enter clinical trials within a year. In addition to our lead program, Senex is developing drugs aimed at two other unique cancer targets.